<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093677</url>
  </required_header>
  <id_info>
    <org_study_id>LIM-0705-CL-003</org_study_id>
    <nct_id>NCT01093677</nct_id>
  </id_info>
  <brief_title>Investigation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance</brief_title>
  <acronym>LIM</acronym>
  <official_title>A Single-Blind,Randomized,Placebo-Controlled Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Exploratory Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Limerick BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Limerick BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      LIM-0705 will gain results on the effects of LIM-0705 on Male Subjects with Impaired Glucose&#xD;
      Tolerance&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no subjects enrolled&#xD;
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of LIM-0705 on glucose metabolism, lipid metabolism and renal function in subjects with impaired glucose tolerance</measure>
    <time_frame>approx. 1 month</time_frame>
    <description>Assessment of glucose metabolism will be based on monitoring of overnight-fasting glucose levels and on performance of an Oral Glucose Tolerance Test (OGTT)&#xD;
Assessment of lipid metabolism will be based on 12 hour-fasting lipid profiles (including LDL, HDL, total cholesterol, free fatty acids, and triglycerides)&#xD;
Assessment of renal function will be performed by monitoring serum BUN and creatinine levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events and pharmacokinetics of LIM-0705 and its major metabolite</measure>
    <time_frame>approx. 1 month</time_frame>
    <description>To evaluate the incidence of treatment emergent adverse events; as well as changes in physical examination findings, vital signs, ECGs, and clinical laboratory tests (serum chemistry, hematology urinalysis, and coagulation)&#xD;
To characterize the pharmacokinetics of LIM-0705 and its major metabolite</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>750 mg of LIM-0705 BID for 14 days. Up to 20 subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID for 14 days. Up to 10 subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIM-0705</intervention_name>
    <description>Oral solution 750 mg LIM 0705 BID for 14 days.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral solution placebo BID for 14 days.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males, age 18-70 years old&#xD;
&#xD;
          2. Measured waist circumference to hip circumference ratio &gt;0.90&#xD;
&#xD;
          3. Body mass index (BMI) of 27 - 40 kg/m2&#xD;
&#xD;
          4. Screening and Day -1 capillary glucose measurement between 110-160 mg/dL (6.1-8.9&#xD;
             mmol/L) after a 12 hour fast&#xD;
&#xD;
          5. Screening and Day -1 OGTT with a 2 hour post-glucose measurement ≥140 mg/dL (7.8&#xD;
             mmol/L) after a 12 hour fast&#xD;
&#xD;
          6. Screening HbA1c &gt; 6 and ≤ 7.5%&#xD;
&#xD;
          7. Subjects must be in reasonably good health as determined by pre-study medical history,&#xD;
             physical examination, 12-lead ECG, and the following laboratory measures:&#xD;
&#xD;
               -  Electrolytes, ALP, LDH, creatinine, and urea must be within normal range without&#xD;
                  medication&#xD;
&#xD;
               -  Urinalysis within normal limits&#xD;
&#xD;
          8. Willing to remain in confinement at the clinical study unit for up to 18 days/17&#xD;
             nights and to return to the unit as specified for additional assessments&#xD;
&#xD;
          9. Willing to consume only the food that is provided by the clinical study unit&#xD;
&#xD;
         10. Non-smokers or &quot;social smokers&quot; (defined as fewer than 5 cigarettes per week) willing&#xD;
             to abstain from smoking for the duration of study&#xD;
&#xD;
         11. Willing to abstain from alcohol-containing, grapefruit-containing, or&#xD;
             caffeine-containing foods or beverages&#xD;
&#xD;
         12. Able to read, understand and follow the study instructions&#xD;
&#xD;
         13. Agree to use of two effective methods of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy to onions or red wine&#xD;
&#xD;
          2. Strict vegetarians (i.e., subjects who do not eat meat, fish, fowl, or dairy)&#xD;
&#xD;
          3. Use of any non-study medication(s) during the study period other than those approved&#xD;
             by the Investigator for treatment of an adverse event (AE)&#xD;
&#xD;
          4. Use of chemotherapy agents or history of cancer, other than non-metastatic&#xD;
             non-melanoma skin cancer that has been completely excised, within five (5) years prior&#xD;
             to the Screening visit&#xD;
&#xD;
          5. Use of any dietary aids or foods known to modulate drug metabolizing enzymes (e.g.,&#xD;
             St. John's Wort, grapefruit juice) within 4 days of randomization&#xD;
&#xD;
          6. History of bacterial or viral infection requiring treatment with antibiotics or&#xD;
             antivirals within 30 days of randomization&#xD;
&#xD;
          7. Difficulty in swallowing oral medications&#xD;
&#xD;
          8. History of seizure disorder&#xD;
&#xD;
          9. Moderate to severe gastro-esophageal reflux disease&#xD;
&#xD;
         10. History of arrhythmia&#xD;
&#xD;
         11. Cognitive or psychiatric disorders, or any other condition that could interfere with&#xD;
             compliance with study procedures and/or confinement in a clinical study unit&#xD;
&#xD;
         12. Baseline liver enzymes greater than the upper limit of normal&#xD;
&#xD;
         13. Baseline creatine phosphokinase (CPK) greater than 2.5x the upper limit of normal&#xD;
&#xD;
         14. History of drug or alcohol abuse&#xD;
&#xD;
         15. Use of any other investigational drug within 30 days of randomization or&#xD;
             investigational biologic within 180 days of randomization&#xD;
&#xD;
         16. Use of over-the-counter (OTC) medications or nutraceuticals, excluding routine&#xD;
             vitamins, within 14 days of randomization or 5 half-lives of the drug, whichever is&#xD;
             longer&#xD;
&#xD;
         17. Use of prescription pharmaceuticals within 30 days of randomization&#xD;
&#xD;
         18. Donation and/or receipt of any blood or blood products within 90 days of randomization&#xD;
&#xD;
         19. Current gastrointestinal (GI), renal, hepatic, or coagulant disorder within 12 months&#xD;
             of randomization&#xD;
&#xD;
         20. History of peptic or duodenal ulcer or GI bleed&#xD;
&#xD;
         21. Subjects with Gilbert's Syndrome&#xD;
&#xD;
         22. Subjects with positive drug or alcohol screen&#xD;
&#xD;
         23. Subject positive for hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg),&#xD;
             or human immunodeficiency virus (HIV) antibody&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Frauman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nucleus Network</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>March 15, 2010</study_first_submitted>
  <study_first_submitted_qc>March 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <last_update_submitted>June 4, 2010</last_update_submitted>
  <last_update_submitted_qc>June 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Wendye Rae Robbins, MD</name_title>
    <organization>Limerick BioPharma</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

